Keratins, formerly known as cytokeratins, are the major epithelial-specific subgroup of intermediate filament proteins. Adult hepatocytes express keratin polypeptides 8 and 18 (K8/K18), while cholangiocytes express K8/K18 and keratins 7 and 19 (K7/K19). Keratins function primarily to protect hepatocytes from apoptosis and necrosis, which was revealed using several genetic mouse models. This cytoprotective function was further clarified by the identification of natural human keratin variants that are normally silent but become pathogenic by predisposing their carriers to apoptosis during acute or chronic liver injury mediated by toxins, virus infection or metabolic stress. During apoptosis, caspases cleave K18 and K19 at conserved aspartates (for human K18/K19: 235 Val-Glu-Val-Asp ↓ ) and K18 at a unique aspartate (for human K18: 394 AspAla-Leu-Asp ↓ ), with the latter exposed epitope becoming recognized by the M30 antibody in blood and tissues. Additional K18-containing protein backbone epitopes are detected using the M6 and M5 (termed M65) antibodies. Intact K18 and its associated fragments, which are released into blood during apoptosis and necrosis in various diseases, have been analyzed by ELISA using the M30/M65 antibodies or their signal ratios. Furthermore, M30/M65 levels have been used as diagnostic and prognostic biomarkers in acute and chronic liver diseases including nonalcoholic steatohepatitis and acute liver failure. Other keratin biomarkers include K18-related tissue Correspondence to: Nam-On Ku; Pavel Strnad; Heike Bantel; M. Bishr Omary. Contact Author Information (for purposes of corresponding with journal): Nam-On Ku (namonku@yonsei.ac.kr), Pavel Strnad (pstrnad@ukaachen.de)
targeting to subcellular compartments, 9 modulation of protein synthesis, 23 organelle positioning 24 and protection from apoptosis and necrosis. [23] [24] [25] This review focuses on hepatobiliary aspects related to: (i) biochemical events that lead to keratin proteolysis by caspases during apoptosis, (ii) keratin functions related to cell injury and death, and (iii) the utility and caveats of measuring keratin fragments as biomarkers of liver injury.
Keratins 18 and 19 digestion by caspases as a posttranslational modification
Keratins undergo several covalent posttranslational modifications (PTMs) including phosphorylation, glycosylation, ubiquitination, sumoylation, transamidation and acetylation. 26 These modifications regulate keratin filament organization, subcellular localization, solubility, turnover, interaction with binding proteins and consequently keratin function. The best understood modification is keratin phosphorylation which is highly relevant because significant increases in keratin phosphorylation occur in the context of cell injury due to activation of stress and other kinases. 26, 27 Keratin phosphorylation is among the earliest biochemical events that take place after an apoptotic stimulus, and mice that express phospho-mutant K18 Ser53Ala 28 or K8 Ser74Ala 29 are predisposed to Fas-mediated liver injury.
Another form of a non-covalent keratin PTM is proteolysis of type-I keratins, including K18 and K19, by caspases during apoptosis. 9 K18 has two caspase recognition sites ( Fig.1 ): VEVD 238 which is conserved across species and most IFs, and a unique DALD 397 site that is present only in K18 and not other keratins/IFs 18, 19, 30 (Table 1) . The caspase-mediated K18 cleavage occurs first at the aspartate of DALD 397↓ and then at VEVD 238↓ , 30, 31 with the first cleavage event occuring early before detection of annexin-V staining and DNA fragmentation. 30, 32 Notably, the unmasked neoepitopes at K18 VEVD 238 or DALD 397 are detected by epitope-specific antibodies: mouse monoclonal M30 antibody recognizes the fragment ending with DALD 397 , while a rabbit polyclonal antibody recognizes the fragment ending with VEVD 238.33,34 Such antibodies provide powerful tools to assess epithelial cell apoptosis by detecting and quantifying apoptotic and nonapoptotic K18 (and K19) species in serum/plasma. The M30 and M65 ELISAs have been used in more than 100 liver and nonliver related studies to assess disease activity and the contribution of apoptosis or total cell death to disease pathogenesis (Supplemental Table 1 ).
Caspase-mediated cleavage of cytoskeletal components, including K18/K19, is presumed to allow reorganization of the filament network, thereby permitting retraction of the affected cells and membrane blebbing that are seen at early stages of apoptosis. 11 Although it is known that the three major cytoskeletal elements are caspase substrates, 14, 15 including cytolinker proteins such as plectin, 35 the orchestration and sequence of cytoskeleton alterations are poorly understood.
The physiological significance of caspase-mediated K18 cleavage appears to be related to allowing keratin filaments to reorganize. This is supported by findings in transgenic mice that overexpress a caspase-resistant K18 mutant (K18-DE) with Asp (D)-to-Glu (E) mutation at the two caspase cut sites (D238/D397). Keratin filaments in livers and isolated hepatocytes from K18-DE mice were not able to reorganize and disassemble upon Fas stimulation in vivo and ex vivo. 34 These mice also developed more severe Fas-triggered liver damage as compared with mice that overexpressed wild-type K18. The enhanced K18 DE liver injury is due to shunting of cell death from apoptosis to necrosis in association with keratin hypophosphorylation 34 at a serine that normally protects from apoptosis when phosphorylated. 29 Hence, K18 caspase cleavage during apoptosis allows for the progression of keratin reorganization during apoptosis (Fig.2) . The mechanism of the shunting of cell death towards necrosis when K18 cleavage is blocked remains to be investigated.
Keratin variants predispose to cell death and liver disease progression
The essential cytoprotective function of keratins is supported by more than 60 different disorders that are linked to the presence of inherited keratin variants (www.interfil.org). [36] [37] [38] For example, KRT8 and KRT18 variants associate with progression of several chronic liver diseases including hepatitis C, primary biliary cirrhosis, and what was initially associated with cryptogenic cirrhosis that is likely primarily due to non-alcoholic fatty liver disease (NAFLD). 39, 40 In addition, K19 G17S substitution associates with disease progression in patients with primary biliary cirrhosis. 41 Further studies are needed to evaluate the biological importance of this and other potential K19 variants. K8/K18 variants also associate significantly with acute liver failure (ALF) progression and the need for liver transplantation or patient death, 42 In addition, K18 (D90H) and K8 (K393R) mutation at residues that disrupt keratin cytoskeletal organization were found in two patients who died from isoniazid and ezetimibe/simvastatin hepatoxicity, respectively. 38 The mechanism by which human keratin variants predispose to liver injury appears to be primarily nonmechanical. For example, some variants impair keratin phosphorylation at adjacent residues which renders K18 more susceptible to digestion by caspases. The mutation-triggered predisposition to apoptosis is pathway-dependent in that two different K18 mutations in transgenic mice predispose to Fas but not TNF-mediated apoptosis. 34, 43 As compared with epidermal keratin mutations, which as a group cause disease and are highly penetrant, K8/K18 variants predispose to (liver) disease rather than cause disease per se, are more common, and display race/ethnic associations. 9, 38, 42 For example, K8 Y54H and G434S are the most common amino-acid-altering variants in individuals of African descent and are found in ~3.6 and ~8% of liver-healthy groups, respectively. 38, 44 In contrast, K8 G62C and R341H are the most abundant substitutions found in Caucasians (variant frequencies 1-2% and ~6%, respectively). 38 The K8/K18 common variants are typically located in less conserved keratin regions (head and tail, Fig.1 ), whereas mutations in the most conserved K8/K18 subdomains are rare (variant frequencies <0.1%). 38 An extensive body of works indicate that keratin variants predispose their carriers to both apoptotic and non-apoptotic cell death depending on the pathologic challenge and location of the mutation. 9, 23, 25, 29, 34, 38 Clinical utility of keratin 18 as a liver disease biomarker Liver biopsy represents the gold standard for diagnosis and evaluation of the activity or progression of liver diseases but it bears important risks. Since a liver biopsy specimen represents ~1/50,000 of the total liver mass, sampling errors might limit interpretations. 45 Intra/inter-observer variability may also contribute to misinterpretations. 46 Much attention has therefore focused on the identification of non-invasive biomarkers that can detect liver disease activity or progression. Increased apoptosis and/or necrosis play a role in the pathogenesis of various liver diseases and determine disease activity and progression. 10, 47, 48 Thus, biomarkers of hepatocyte apoptosis or necrosis have been used to monitor acute and chronic liver diseases. During hepatocyte apoptosis, activated caspases cleave K18 which can be detected in serum or plasma by the M30 ELISA 49 whereas the M65 ELISA detects both caspase-cleaved and uncleaved (total) K18. 49, 50 Several mechanisms may contribute to K18 release to the extracellular space. As such, K18 fragments form cytoplasmic inclusion bodies and occur in apoptotic cell surface blebs, 51 and keratins can circulate in serum within extracellular vesicles. 52 Further studies are needed to delineate the modes of keratin release from cells (e.g., within vesicles, apoptotic bodies, full length, apoptotic and nonapoptotic fragments). Findings from these studies will likely refine the currently-used assays and enhance their utility.
Here, we summarize studies to date that have utilized keratins as potential biomarkers in acute and chronic liver disease. We focus on primary hepatobiliary diseases although the M30/M65 ELISAs have been used in other glandular-tissue-type injury such as gastrointestinal/liver graft-versus-host disease. 53 
Role of K18 biomarkers in acute liver diseases
Acute liver failure (ALF) is potentially life-threatening whereby the decision for liver transplantation should be made as early as possible. Therefore, non-invasive biomarkers are urgently needed. Notably, ALF patients have significantly higher circulating levels of caspase-cleaved (M30) and presumed total K18 (M65), as compared to healthy individuals. 50, 54, 55 Whether apoptotic and/or necrotic cell death predominates in ALF and how their proportion influence the outcome remain largely unclear and likely depend on the etiology, severity and duration of the ALF. 56 Nevertheless, it was demonstrated that modification of the model for end-stage liver disease (MELD) score by substitution of bilirubin with total K18 significantly improved the prediction of ALF outcome at the day of hospital admission. 57 Moreover, the US ALF Study Group proposed an ALF index which combines clinical markers and M30 levels and thus allowed better prediction of ALF outcome as compared to the routinely used King's College Criteria (KCC) or MELD score. 58 However, although serological detection of M65 or M30 levels allowed the prediction of ALF outcome in paracetamol-intoxication, 59 , 60 neither M30 nor M65 levels were superior to KCC in those patients. 61 Thus, combination of these cell death biomarkers with other prognostic parameters of ALF might be required to improve the assessment of ALF outcome.
Role of K18 biomarkers in chronic liver diseases Viral hepatitis
Chronic hepatitis B or C virus (HBV/HCV) infections are accompanied by variable degrees of hepatic inflammation and fibrosis. Apoptosis plays an important role in inflammatory liver damage and fibrosis progression, and is associated with increased risk of cirrhosis and hepatocellular carcinoma. 62 For example, caspase-mediated K18 cleavage correlated with inflammatory disease activity in livers from patients with chronic HCV infection. 49 Similarly, patients with chronic HBV infection showed higher serum M30 levels compared to healthy controls. 63 M30 serum levels correlated with histological disease activity in chronic HCV or HBV infection. 64, 65 Vice versa, M30 levels declined with successful antiviral treatment of chronic HCV or HBV infection. 66, 67 Elevated M30 levels could even be detected in sera from patients with chronic HCV or HBV infection and normal aminotransferase activity. 49, 63, 68 In this respect, patients with HBeAg-negative chronic HBV infection and transiently normal aminotransferases had higher M30 serum levels compared to inactive carriers. 63 Interestingly, the majority of patients with chronic HCV infection and normal aminotransferase levels had histological evidence of progressive fibrosis, 49 which is consistent with other studies showing elevated M30 levels in association with advanced fibrosis or cirrhosis (Supplemental Table 1 ). 68, 69 Both, apoptosis and necrosis have been proposed as responsible for development and progression of liver fibrosis. 62 Unlike the M30 ELISA, however, detection of total K18 by the M65 ELISA might allow the discrimination of lower fibrosis stages in chronic liver disease. 69 Whether differential sensitivity in detection of lower fibrosis stages between the M30 and M65 assays reflects different cell death modes or whether different stability of the K18 forms might influence the sensitivity remains to be investigated.
Non-alcoholic fatty liver disease
NAFLD is one of the most common causes of chronic liver diseases, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) with the risk of developing liver cirrhosis and HCC. 70 Notably, aminotransferase levels are within the normal range in nearly 80% of patients with fatty liver. 71 However, NASH can be diagnosed in up to 59% of patients despite normal aminotransferases, 72, 73 and >50% of patients with steatosis progress toward NASH and more than half of them develop fibrosis progression within 3 years. 74 Therefore, novel biomarkers to detect NAFLD activity and to monitor disease progression are needed. Since hepatocyte apoptosis plays a critical role in NAFLD-associated liver injury, and aminotransferases are not sensitive enough for the diagnosis of NASH, the M30 assay became an extensively evaluated marker for detecting NAFLD activity. 75 Early studies showed that plasma M30 is higher in patients with NASH compared to steatosis, and might allow discrimination between both entities. 76 Subsequent studies (Supplemental Table 1 ) confirmed an increase of caspase-cleaved K18 fragments in NASH patients compared to patients with simple steatosis. 69 The diagnostic performance of K18 fragments in NASH detection was promising with area under the curve (AUC) values ranging from 0.77-0.93. 77 However, the diagnostic performance of caspase-cleaved K18 for detection of NASH has been recently questioned, 78 given that AUC values of 0.65 and of 0.68 were calculated for prediction of NASH or fibrosis, respectively, in NAFLD patients. 78 Nevertheless, plasma/serum K18 fragment levels were significantly higher in NAFLD patients with moderate to severe fibrosis compared to those with no or mild fibrosis. 77, 79 Moreover, K18 fragments correlated significantly with the degree of steatosis, lobular inflammation and ballooning 77, [79] [80] [81] and more accurately reflected histological NAFLD activity score (NAS) 82 compared to ALT levels. 81 In addition, changes in M30 levels closely paralleled NAS 75,81 which was not observed for aminotransferase levels. 81 Another study confirmed a significantly stronger decrease of M30 levels in patients with histological improvement compared to those without changes in NAS, although reductions in M30 levels were not better than ALT levels for identification of patients with histological NAFLD improvement. 83 Similarly, M30 levels declined significantly in parallel with aminotransferase levels in NAFLD patients following bariatric surgery. 77 In contrast to M65, M30 was unable to predict NASH independently of ALT levels. 69 In line with this observation, a composite model including both ALT and caspase-cleaved K18 revealed a higher accuracy for prediction of NAFLD activity compared to detection of caspase-cleaved K18 alone. 84 Otherwise, a higher diagnostic performance of total K18 compared to caspase-cleaved K18 for prediction of NASH could be demonstrated. 85, 86 Further studies are needed to explore whether total K18 levels might be superior for predicting and monitoring of NAFLD disease activity. In summary, the M30 and M65 ELISAs represent a reliable and sensitive method for non-invasive detection of liver disease activity and progression, and have been extensively evaluated in NAFLD (Fig.3) . Furthermore, assessment of K18 fragments became part of prospective NAFLD studies 74, 87 and such data will help our understanding of the usefulness of K18-based biomarkers in this context.
Keratin fragments in liver cancer and nonmalignant liver diseases
While M30/M65 currently represent the most widely used keratin-based serum markers, other tumor markers also rely on detection of keratin fragments. For example, tissue polypeptide antigen (TPA) recognizes K8, K18 and K19; whereas tissue polypeptide specific antigen (TPS) and keratin fragments 21-1 (CYFRA 21-1) detect only K18 and K19, respectively. Several commercial assays exist for these markers 88 (Fig.4) . The epitopes recognized by M65 and TPS are localized in the C-terminal portion of the rod domain, with TPS being restricted to K18 amino acids 322-340 89, 90 (Fig.1) . Although the diagnostic benefit of TPS, TPA and CYFRA 21-1 have been evaluated in multiple human malignancies and showed prognostic value particularly in breast and lung cancers, these markers are not routinely used in the clinic due to their low sensitivity. 88 CYFRA 21-1 might have prognostic relevance in HCC 91, 92 but further studies are needed to clarify its usefulness. Given the emerging negative prognostic value of K19 expression in HCC, 93 future studies should assess the ratio between serum K19 (CYFRA 21-1) and K18 levels (M65/TPS). Finally, CYFRA 21-1 and/or serum K19/K18 ratio may be helpful to discriminate between HCC and intrahepatic cholangiocarcinoma given that the latter displays stronger K19 expression. 94 Numerous reports have assessed the potential usefulness of the above-mentioned tumor markers in liver disease. For CYFRA 21-1, the diagnostic benefit in non-malignant liver diseases is likely small given that K19 is expressed only in cholangiocytes in unstressed livers and even upon injury, hepatocellular K19 levels are rather low. 9 Although CYFRA 21-1 has not been adequately assessed in cholestatic liver disorders, it has been studied in the context of other liver diseases. For example, patients with alcoholic hepatitis displayed increased CYFRA 21-1 levels 95 which meshes well with the associated strong ductular reaction. 96 Unlike CYFRA 21-1, TPA and TPS are commonly elevated in patients with both malignant and non-malignant liver diseases and therefore lack sufficient specificity for HCC detection. 97 On the other hand, increased TPS levels may predict early HCC recurrence after curative resection. 97 In cirrhosis, TPA strongly correlates with (but might be more sensitive than) AST values. 98 Moreover, TPA might discriminate between non-cirrhotic and cirrhotic subjects given that it correlates with hepatic vein pressure gradient, a central parameter of portal hypertension. 99 TPS was found to be elevated in patients with multiple non-malignant liver diseases and to correlate with AST levels and histological score of disease severity. 100 Of note, TPS was elevated in one third of liver disease patients with normal liver enzyme values suggesting that it might be more sensitive than AST. 100 In alcoholic liver disease subjects, TPS was lower in those with less severe steatosis/fibrosteatosis compared to those with life-threatening alcoholic hepatitis. 101 TPS levels also correlated with the extent of Mallory-Denk bodies (K8/K18-containing inclusions characteristic of alcoholic liver disease/NASH) 9 but the clinical significance of this finding remains unknown. 101 In NAFLD, one study found TPS to be superior to ALT in discriminating NASH from simple steatosis. 102 Despite these interesting findings, more work is needed on TPA/TPS to evaluate whether or not they offer advantage to already established parameters. Given their biological similarity, it is tempting to speculate that TPS and M65 might be equally useful for subclassification of non-malignant liver disorders.
Conclusion and Caveats of measuring keratin fragments during liver injury
For liver injury, the M30 ELISA is a biologically-sound reflection of the extent of earlystage hepatocyte/cholangiocyte apoptosis, though necrosis may accompany apopotis. However, M30 does not measure late apoptosis stages that include generation of the second K18 caspase cleavage product and, at least in cell culture systems, the M30 reactivity disappears in some apoptotic cells while reactivity of the antibody that recognizes the K18 second-cut site persists. 33 Moreover, an important unknown is the stability of various keratin species in serum in the context of different liver diseases. This caveat applies to all the currently-used ELISAs that detect M30/M65/TPA/TPS/CYFRA 21-1.
With regard to the M65 ELISA, it is used to measure serum/plasma total or fragment K18 species using the monoclonal antibodies M5 and M6 whose epitopes are located between K18 amino acids 300-380 90 (Fig.1) . Hence, M65 detects not only nonapoptotic K18 fragments and intact K18, but also the 159aa apoptotic K18 fragment. This indicates that the M65 ELISA does not exclusively represent nonapoptotic K18, and that M65 may overlap with TPA and TPS depending on the biologic and clinical contexts.
Another variable that is usually not accounted for in studies that measured keratin fragments is the presence of nonhepatic epithelial tissue injury or inflammation (gastrointestinal, lung, kidney; tissues that express K8/K18/K19). Such extra-hepatobiliary organ involvement could provide false-positive readings of K8/K18/K19 fragments, since these keratins and their fragments can also spill into the circulation.
While numerous studies have measured keratin fragments as biomarkers of liver (Fig.3 and Supplemental Table 1 ) and other tissue injury, it is important to have a better appreciation of the species that are being measured. For example, it would be meaningful to compare the M30/M65 assays with (currently unavailable) ELISAs that would detect epitopes spanning the undigested K18 aspartates 238 and 397. Also, there is no available ELISA that is directed to K18 Asp238, and such an ELISA once established is predicted to recognize both K18/K19 aspartates given their conserved proximal sequence. Mass spectrometry and other immunobiochemical tools may also help define the precise nature of the keratin species in sera from patients with different liver and other diseases that associate with release of K8/K18/K19 species. For example, it is possible that PTMs of circulating keratin species may provide an added dimension to use as biomarkers. 26 In conclusion, the detection of circulating keratin species remains a useful adjunct for the assessment of liver injury. The abundance of keratins in liver tissue, coupled with their relative stability, 9, 33 provide important support for their use as durable and sensitive liver injury biomarkers. Furthermore, the nature of keratin fragments (apoptotic vs nonapoptotic) might provide insight regarding the cause(s) of hepatocyte injury. Better understanding of the mode of release and biochemical form of circulating keratins will likely enhance their diagnostic and potential prognostic utility.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Mutation of the two K18 caspase cleavage sites (K18 DE) results in several consequences including keratin hypophosphorylation, inability of the keratin filaments to reorganize, and shunting towards cell necrosis rather than apoptosis. Number of published original articles using K18 biomarkers (M30 or M65) in NAFLD (n=70), HBV (n=10), HCV (n=17), and other liver diseases (n=45).
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